- Home
- RPTX vs ATYR Comparison
RPTX vs ATYR Comparison
Compare RPTX & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RPTX | ATYR |
|---|---|---|
| Founded | 2016 | 2005 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 92.4M | 79.2M |
| IPO Year | 2020 | 2015 |
Fundamental Metrics
Financial Performance| Metric | RPTX | ATYR |
|---|---|---|
| Price | $2.57 | $0.73 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 6 |
| Target Price | $3.00 | ★ $8.75 |
| AVG Volume (30 Days) | 1.3M | ★ 2.0M |
| Earning Date | 11-14-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $11,870,000.00 | $190,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2,122.22 | $18,728.88 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.89 | $0.64 |
| 52 Week High | $2.66 | $7.29 |
Technical Indicators
Market Signals| Indicator | RPTX | ATYR |
|---|---|---|
| Relative Strength Index (RSI) | 74.94 | 42.35 |
| Support Level | $2.15 | $0.69 |
| Resistance Level | $2.66 | $0.76 |
| Average True Range (ATR) | 0.06 | 0.04 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 83.96 | 29.49 |
Price Performance
Historical ComparisonAbout RPTX Repare Therapeutics Inc.
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations.
About ATYR aTyr Pharma Inc.
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.